Deadline for applications from lead plaintiffs: January 8, 2027. Investors who purchased securities (Nasdaq ticker: CVRX) between July 25, 2023, and August 6, 2026, may be eligible to recover their losses.

New York, November 13, 2026 / PRNewswire / -- Attorney Ad -- This lawsuit is intended to represent all individuals and entities that purchased or otherwise acquired CVRx securities between July 25, 2023, and August 6, 2026, in order to seek compensation for damages caused by the defendant's alleged violations of federal securities laws. All of the aforementioned dates are included within the "class action period." The law firm encourages interested investors to visit their website bgandg.com / cases / cvrx-inc-cvrx-class-action-lawsuit to join this case.

CVRx Case Details

The indictment alleges that throughout the duration of the class action, the defendant made false and/or misleading statements, and/or failed to disclose the following facts:

• To drive sales growth, CVRx and/or its employees engaged in illegal and unsustainable sales practices, including improper marketing Barostim, offering or paying bribes, as well as providing false information to government healthcare programs, in violation of the False Claims Act ( False Claims Act ) and the Bribes Act ( Anti - Kickback Statute );
• The income from CVRx comes from the aforementioned alleged illegal activities, hence it is not sustainable;
• Alleged illegal sales and marketing activities increase the risk of criminal and civil liabilities; as well as
• Therefore, the defendant's statements regarding the company's reported revenue, the so-called growth drivers, compliance with the 'False Statements Act' and the 'Anti-Bribery Act', patient admission and reimbursement policies, as well as the internal controls over financial reporting, are materially false and misleading.

The indictment further alleges that the defendant made significant false and misleading statements regarding the reorganization of the CVRx sales team and the transformation of the business organization.

CVRx What should investors do next?

A class action has been filed. If you would like to view a copy of the complaint, you can visit the website of that law firm: bgandg.com / cases / cvrx-inc-cvrx-class-action-lawsuit. You may also contact the lawyers or client relationship managers at Bronstein, Gewirtz, Grossman, and LLC, Nathan Miller, at telephone number 917-590-0911. If you have suffered losses due to holding CVRx, you may request the court to appoint you as the lead plaintiff before January 8, 2027. By sharing in any recovery of funds, you are not required to serve as the lead plaintiff.

CVRx Investors do not need to bear any fees.

We, Bronstein, Gewirtz & Grossman LLC, represent the investors in the class action as risk agents. This means that only in the event of our victory will we request the court to reimburse our out-of-pocket expenses and attorney fees, which are usually a certain percentage of the total amount recovered.

Why choose Bronstein, Gewirtz, Grossman, and LLC to act as proxies for the CVRx securities class action?

Bronstein, Gewirtz & Grossman, LLC is a nationally renowned law firm that represents investors in securities fraud class actions and shareholder derivative lawsuits. The firm has recovered hundreds of millions of dollars for investors across the United States. For more information, please visit www.bgandg.com.

The founding partner, Peretz Bronstein, stated: "Our focus is on restoring investors' capital and ensuring corporate accountability, which helps to maintain the fundamental integrity of the market."

Follow our LinkedIn, X, Facebook, or Instagram to get updates.

Contact Information

Peretz Bronstein Lawyers or Nathan Miller

Lawyer advertisement.

Past results do not guarantee similar outcomes in the future.